A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data ...

The following is a summary of “Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network,” published in the ...

Assertio (NASDAQ:ASRT – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Monday. Separately, HC ...

From wetting the bed to acne, we have crunched the numbers on the success rate of every single disability claim. It comes ...